Asia Pacific Skin Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Non-Melanoma and Melanoma), By Test Type (Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others), ByEnd-use, By Country and Growth Forecast, 2024 - 2031

Analysis of Market Size & Trends

The Asia Pacific Skin Cancer Diagnostics Market would witness market growth of 5.9% CAGR during the forecast period (2024-2031).

The China market dominated the Asia Pacific Skin Cancer Diagnostics Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $851.6 million by 2031. The Japan market is registering a CAGR of 5.4% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 6.7% during (2024 - 2031).

The skin cancer diagnostics market is experiencing substantial growth due to the increasing cost of healthcare, which is indicative of the broader patterns in global health investment. According to the World Health Organization (WHO), global healthcare spending reached $8.3 trillion in 2020, accounting for approximately 10% of global GDP.

Moreover, Various factors fuel this upward trajectory in healthcare spending, including aging populations, advances in medical technology, and increased awareness and diagnosis of health conditions, including skin cancer.

Many countries within the Asia Pacific region are undergoing significant advancements in healthcare infrastructure. This includes the establishment of new hospitals, clinics, and diagnostic facilities. Improved access to these facilities fosters a more proactive approach to skin cancer screening and diagnosis. China has experienced a significant rise in skin cancer incidence, partly due to the rapid development of healthcare infrastructure.

Free Valuable Insights: The Global Skin Cancer Diagnostics Market is Predict to reach USD 12.8 Billion by 2031, at a CAGR of 5.3%

Based on Type, the market is segmented into Non-Melanoma and Melanoma. Based on Test Type, the market is segmented into Skin Biopsy, Imaging Tests, Dermatoscopy, Lymph Node Biopsy, and Others. Based on End-use, the market is segmented into Hospital & Clinics, Laboratories, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

List of Key Companies Profiled

• Castle Biosciences, Inc.
• Bausch Health Companies, Inc. (DermTech, Inc.)
• Canfield Scientific, Inc.
• DermaSensor, Inc.
• F.Hoffmann-La Roche Ltd.
• NeoGenomics, Inc.
• Quest Diagnostics Incorporated.
• Digital Diagnostics, Inc. (3Derm Systems, Inc.)
• FotoFinder Systems GmbH
• Veriskin Inc

Asia Pacific Skin Cancer Diagnostics Market Report Segmentation

By Type

• Non-Melanoma
• Melanoma

By Test Type

• Skin Biopsy
• Imaging Tests
• Dermatoscopy
• Lymph Node Biopsy
• Others

By End-use

• Hospital & Clinics
• Laboratories
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific